Who Paid My Doc
Ryan Ruger
Interventional Pain Medicine Billings, MT Medical Doctor
NPI 1104567825 CMS profile 11912996
3490 Gabel Rd Ste 100, Ste 100, Billings, MT 59102
General payments
$34
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ryan Ruger of Billings, MT is reported in the CMS Open Payments database as having received $34 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $34 | 1 |
Beside peers
- Ryan Ruger
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Ryan Ruger were reported at $34. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Ryan Ruger | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $684 | $216–$2,079 | $163 |
| 2020 | $0 | $382 | $122–$1,109 | $114 |
| 2021 | $0 | $552 | $167–$1,554 | $132 |
| 2022 | $0 | $605 | $187–$1,924 | $149 |
| 2023 | $0 | $671 | $195–$1,915 | $160 |
| 2024 | $0 | $684 | $206–$1,837 | $164 |
| 2025 | $34 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
632
Drug cost
$91,120
Branded share of claims
25.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 50 | $43,052 | |
| Rybelsus Semaglutide | Brand | 18 | $25,475 | |
| Ozempic Semaglutide | Brand | 12 | $11,888 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 17 | $2,567 | |
| Gabapentin | Generic | 46 | $1,261 | |
| Bumetanide | Generic | 13 | $941 | |
| Atorvastatin Calcium | Generic | 70 | $916 | |
| Metformin Hcl Er Metformin Hcl | Brand | 39 | $847 | |
| Olanzapine | Generic | 13 | $723 | |
| Levothyroxine Sodium | Generic | 41 | $440 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Interventional Pain Medicine in Montana
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Montana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.